Climb Bio, Inc.
NASDAQ:CLYMBiotechnology
Healthcare
$9.78 +0.17%
+$0.02 today
- Market cap
- $574.46M
- Beta
- 0.10
- P/E (TTM)
- -14.7
- EPS (TTM)
- -$0.77
52W Low $1.17High $12.48
Volume 0.59M
Average 0.88M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$67.88M
FY 2025 · Annual
Net Income
-$59.85M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 97K |
| Gross Profit | 0 | 0 | 0 | 0 | (97K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 23.32M | 26.21M | 15.41M | 14.34M | 46.62M |
| Selling, General & Admin | 12.35M | 18.92M | 24.86M | 16.03M | 21.17M |
| Operating Expenses | 35.67M | 45.14M | 40.28M | 82.02M | 67.79M |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 97K |
| EBITDA | (47.48M) | (45.24M) | (35.12M) | (30.36M) | (59.75M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (35.67M) | (45.14M) | (40.28M) | (82.02M) | (67.88M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 1.38M | 4.62M | 8.13M | 8.32M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (11.81M) | (109K) | 5.16M | 8.12M | 8.03M |
| Income Before Tax | (47.48M) | (45.24M) | (35.12M) | (73.9M) | (59.85M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (47.48M) | (45.24M) | (35.12M) | (73.9M) | (59.85M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (4.24) | (1.72) | (1.30) | (1.53) | (0.88) |
| EPS (Diluted) | (4.24) | (1.72) | (1.30) | (1.53) | (0.88) |
| 12.26M | 26.31M | 26.99M | 48.16M | 67.81M | |
| 12.26M | 26.31M | 26.99M | 48.16M | 67.81M |
CLYM Earnings Waterfall · TTM
NASDAQ:CLYM · Revenue to Net Income
Key Ratios
EPS$-0.78
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-4.4
P/S Ratio0.0
Analysis
$0 of revenue converted into -$52.8M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-0.78, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13D/A | SC 13D/A filing | Nov 9, 2026 | |
| SC 13G/A | SC 13G/A filing | Nov 5, 2026 | |
| S-3ASR | S-3ASR filing | Nov 5, 2026 | |
| 10-Q | Quarterly report | Nov 5, 2026 | |
| 8-K | Current report | Nov 5, 2026 |
How much revenue does CLYM generate?
Climb Bio, Inc. (CLYM) reported $0.00 of revenue in fiscal 2025.
Is CLYM profitable?
Climb Bio, Inc. (CLYM) reported -$59.85M of net income.
Continue the stock analysis
Jump to another research area for this company.